Amivantamab for advanced penile cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a new drug called amivantamab for penile cancer that has spread and hasn't responded to earlier treatments. The drug may block signals that help cancer grow. The study also looks at how the HPV virus affects treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have penile cancer that has spread or can't be removed with surgery or cured with radiation.
- You can have had up to 2 prior cancer treatments, but your cancer must have grown during or right after a platinum-based chemo (like cisplatin).
- A sample of your tumor (from a biopsy or surgery) must be available for HPV testing.
- You must be a man between 18 and 85 years old.
- You must be able to care for yourself (ECOG score 0 or 1) and have a life expectancy of at least 12 weeks.
- You cannot have untreated brain metastases or a history of lung inflammation (pneumonitis) that needed steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called amivantamab, either alone or with other treatments, for people with head and neck cancer that has spread or come back. The goal is to see if the drug can help shrink tumors or control the cancer.
This Phase 1/2 study tests amivantamab alone or combined with standard chemotherapy to treat advanced or metastatic colon or rectal cancer. You may be able to join if your tumor has the right genetic profile (typically “wild-type” for certain genes and no HER2 amplification) and your cancer has measurable or biopsy-able lesions.
This Phase 2 study tests amivantamab (an antibody medicine) in people with advanced or metastatic non-small cell lung cancer that has specific EGFR gene changes. It may help shrink tumors or control cancer when standard curative treatments aren’t possible.
This trial tests whether the drug amivantamab combined with a single chemotherapy drug can help people with advanced non-small cell lung cancer that has a specific EGFR gene mutation (exon20 insertion). It is for people who cannot safely receive standard platinum-based chemotherapy.
This trial tests whether adding the drug amivantamab to usual treatments helps people with advanced head and neck cancer that has come back or spread. It compares the combination to standard care alone.
This trial tests two treatment combinations for people with a specific type of advanced lung cancer that has an EGFR mutation. One group gets amivantamab plus lazertinib, and the other gets amivantamab plus chemotherapy. The goal is to see which combo works better.
Hear when a new Penile Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.